Role of drinking and dietary factors in effective dissolution therapy and recurrence prevention of uric acid kidney stones


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The use of alkaline mineral waters leads to alkalization of urine and an increase in level of urinary citrate, which represent important factor inhibiting the formation of urinary stones. Combination of alkaline mineral waters with citrates facilitates the achievement of target urine pH level not only during dissolution therapy, but also during recurrence prevention. Alkalization of urine and reducing of the influence of alimentary factor don’t preclude drug therapy. Patients should be counselled about complex strategies aimed to modifiable risk factors for urinary stone disease.

Full Text

Restricted Access

About the authors

V. S Saenko

FGAOU VO of I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia (Sechenov University)

Email: saenko_vs@maiI.ru
MD, professor at the Institute of Urology and Male Reproductive Health

S. V Pesegov

FGAOU VO of I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia (Sechenov University)

Ph.D., urologist at the Institute of Urology and Male Reproductive Health

E. A Frolova

FGAOU VO of I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia (Sechenov University)

urologist at the LDO №2 of Institute of Urology and Male Reproductive Health

References

  1. Fisang С., Anding R., Lats S., Laude N.; Dtsch Arztebl Int. 2015;112: 83-91.
  2. Sorokin I., Mamoulakis C., Miyazawa K., Rodgers A., Talati J., Lotan Y. Epidemiology of stone disease across the world. World J Urol. 2017;35(9):1301-1320.
  3. Джавад-заде С.М. Мочекаменная болезнь в эндемическом регионе: этиопатогенез, клиника, лечение. Дисс. докт. мед. наук. М., 1997
  4. Константинова О.В. Прогнозирование и принципы профилактики мочекаменной болезни. Дисс д-ра мед. наук, М., 199
  5. Daudon M., Dore J.-C., Jungers P., Lacour B. Changes in stone composition according to age and gender of patients: a multivariate epidemiological approach. Urol. Res. 2004;32,:241-247.
  6. Adair L.S., Popkin B.M. Are child eating patterns being transformed globally? Obes Res. 2005;13:1281-1299.
  7. Lotan Y., Antonelli J., Jmйnez I.B., Gharbi H., Herring R., Beaver A., Denni A., Von Merveldt D., Carter S., Cohen A., Poindexter J., Moe O.W.,. Pearle M.S The kidney stone and increased water intake trial in steel workers: results from a pilot study. Urolithiasis 2016. doi: 10.1007/s00240-016-0892207.
  8. Marangella M. Use of citrate in patients with nephrolithiasis. G. Ital. Nefrol. 2017;34(4):51-60. PMID: 28762682.
  9. Tracy C.R., Pearle M.S. Update on the medical management of stone disease. Curr Opin Urol. 2009;19(2): 200-204.
  10. Baumann J.M., Affolter B., Caprez U., Clivaz C., von Arx U. Role of calcium in the aggregation of particles coated by urinary macromolecules. Urol Int 2009;82:459-463.
  11. Chemistry and life. 1994, № 1. Russian (Химия и жизнь. 1994. № 1).
  12. Pytel’ Yu.A., Zolotarev I.I. Uric acid kidney stones. 1995, p. 23-24. Russian (Пытель Ю.А. Золотарев И.И. Уратный нефролитиаз. 1995. С. 23-24).
  13. Johnson R.J., Titte S., Cade J.R., Rideout B.A., Oliver W.J. Uric acid, evolution and primitive cultures. Semin Nephrol. 2005;25:3-8.
  14. Emmerson B.T., Gordon R.B., Johnson L.A. Urate Kinetics in Hypoxanthine - guanine Phosphoribosyltransferase Deficiency: Their Significance for the Understanding of Gout. Quart. J. Med. 1976;45:49-61.
  15. Pak C.Y., Sakhaee K., Peterson R.D., Poindexter J.R., Frawley W.H. Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney international. 2001;60(2):757-761.
  16. Alvarez-Nemegyei J., Medina-Escobedo M., Villanueva-Jorge S., Vazquez-Mellado J. Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed? J Rheumatol. 2005;32(11):2189-2191.
  17. Curhan G.C., Taylor E.N. 24-h uric acid excretion and the risk of kidney stones. Kidney international. 2008;73(4):489-96.
  18. Sakhaee K., Adams-Huet B., Moe O.W., Pak C.Y. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney international. 2002;62(3):971-979.
  19. Eisenberg H., Connor T.B., Howard J.E. A useful agent for oral alkali therapy. The Journal of clinical endocrinology and metabolism. 1955;15(4):503-505. doi: 10.1210/jcem-15-4-503.
  20. Maalouf N.M. et al. Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol. 2010;5(7):1277-1281.
  21. Lieske J.C. et al. Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study. Am J Kidney Dis. 2006;48(6):897-904.
  22. Kocvara R., Louzensky G., Ptacek V. Detection of metabolic disorders as a cause of urolithiasis in clinical practice. Cas Lek Ctsk. 1989;128(10): 295-298.
  23. Hinck B.D., Ganesan V., Tarplin S., Asplin J., Granja I., Calle J., Sivalingam S., Monga M. Can a Simplified 12-Hour Nighttime Urine Collection Predict Urinary Stone Risk? Urology. 2017;108:40-45.
  24. Саенко В.С., Газимиев М.А., Песегов С.В. Место минеральных вод в метафилактике мочекаменной болезни. Урология. 2016; S2:87-94
  25. Touhami M. et al. Lemon juice has protective activity in a rat urolithiasis model. BMC Urology 2007:18 https://doi.org/10.1186/1471-2490-7-18
  26. Grases F. et al. Phytotherapy and renal stones: the role of antioxidants. A pilot study in Wistar rats Urol Res 2009;37:35-40. doi: 10.1007/s00240- 008-0165-1.
  27. Siddiquia W.A., Shahzada M., Shabbirb A., Ahmadc A. Evaluation of anti-urolithiatic and diuretic activities of watermelon (Citrullus lanatus) using in vivo and in vitro experiments. Biomedicine & Pharmacotherapy 97. 2018;1212-1221.
  28. Birowo P., Widyahening I.S. Effect of citrus-based products on urine profile: A systematic review and meta-analysis. Nur Rasyid. 2017;6:220. doi: 10.12688/f1000research.10976.1.
  29. Fakhoury M.Q., Gordon B., Shorter B., Renson A., Borofsky M.S., Cohn M.R., Cabezon E., Wysock J.S., Bjurlin M.A. Perceptions of dietary factors promoting and preventing nephrolithiasis: a cross-sectional survey. World J Urol. 2018. doi: 10.1007/s00345-018-2562-6.
  30. Turk C., Neisius A., Petrik A., Seitz C., Skolarikos A., Tepeler A., Thomas K. EAU guidelines on urolithiasis. 2017.
  31. Рапопорт Л.М., Цариченко Д.Г., Саенко В.С., Фролова Е.А. Возможности цитратной терапии в лечении пациентов с мочекаменной болезнью. Фарматека. 2016;s1: 40-43

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies